What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “\[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastric or esophageal cancers.”In the company’s words, NCT07217704 on ClinicalTrials.gov
- Tested for
- Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction, Pancreatic Ductal Adenocarcinoma (PDAC)
- Main trialPhase 3
- “This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \[¹⁸F\]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \[¹⁸F\]FAPI-74 PET/CT using a…”In the company’s words, NCT07217704 on ClinicalTrials.gov
Other drugs for Esophageal Cancer
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- DurvalumabAstraZeneca · Phase 3
- RilvegostomigAstraZeneca · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
Coming up2
- 30 Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Aug 2027 | Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | |
| Phase 3Recruiting | 31 Dec 2027 | Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) | |
| Phase 2Completed | 30 Jun 2025 | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026